gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · NTLAHealthcareDiagnostics

Intellia Therapeutics, Inc (NTLA)

$12.31+3.79%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$11.86▼ 9.26% in range
Nov 3, 2025Low $8.04 · High $17.84Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Intellia Therapeutics closed at $12.31 on Nov 4, up 3.79%, 31.0% below its 52-week closing high. Volume of 3.2M shares was 0.61× its 20-day average (below normal).

Split-adjusted performance: -0.5% over one month, -11.1% over six months, -5.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $7.66M, down 46.2% from a year earlier, with a net margin of -1392.3%.

Short interest was 44.4M shares at the Oct 15 settlement, down 1.5% from the prior report (38.6% of float, 6.5 days to cover).

Market cap$1.72B140.1M shares
Revenue · quarter$7.7M−46.2% YoY
Diluted EPS$-0.80—
P/E · TTM—P/S 29.0×
Net margin-1,392.3%Gross 100.0%
Dividend yieldNone
52-week range8.04 – 17.84−31.0% from high
Volume3.2M0.61× 20-day avg
Volatility · 60d63.0%Annualised
Short % of float38.6%6.5 days to cover
Net cash$437.8MCash $437.8M
Next earnings—Not scheduled
Split-adjusted performance
1W −7.6%1M −0.5%3M +9.5%6M −11.1%YTD +36.9%1Y −5.8%3Y −48.3%5Y −90.5%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Diagnostics

Percentile among 15 companies (100 = best)

6-month momentum36
Revenue growth17
Net margin33
Value (low P/E)—
Size71

Industry medians: 6-month return +17.4%, revenue growth −2.0%, net margin −26.0%, P/E 46.6×.

Short interest

Details →
Shares short44.4M−1.5% vs prior
Days to cover6.5Settled Oct 15
% of float38.6%
Short vol. 10d42.5%of daily volume

Closest peers by size in Diagnostics

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
NTLAIntellia Therapeutics$12.31+3.79%−11.1%−46.2%−1392.3%—$1.72B
CLDXCelldex Therapeutics$29.93+0.74%−13.0%−97.0%−334104.5%—$2.35BCompare
NEOGNeogen$12.46+2.98%+35.7%+6.5%−5.3%—$2.72BCompare
QDELQuidelOrtho$14.35+1.85%+30.9%+2.8%−14.7%—$984.1MCompare
ACHVAchieve Life Sciences$6.98+3.71%+45.4%———$719.7MCompare
MYGNMyriad Genetics$6.02−0.33%+46.5%−10.5%−22.7%—$575.8MCompare
TKNOAlpha Teknova$7.37+0.41%+102.5%+18.5%−26.0%—$454.7MCompare
LNTHLantheus Holdings$101.14+0.34%+17.4%+2.7%19.3%24.0$6.60BCompare
ICCCImmucell$10.37+1.17%+19.7%+11.5%25.5%119.6$94.2MCompare

News about Intellia Therapeutics

All news →
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026GlobeNewswire Inc. · 6d ago▲ PositiveIntellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?Zacks Investment Research · Oct 9, 2026NeutralIntellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 MillionGlobeNewswire Inc. · Sep 4, 2026▲ PositiveIntellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewswire Inc. · Sep 4, 2026▲ PositiveWall Street Expects This Growth Stock That's Already Climbed 70% to Almost Double -- And Here's Why.The Motley Fool · Jun 24, 2026▲ Positive

Quick answers

What does Intellia Therapeutics do?
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA.
What is NTLA's market cap?
$1.72B, based on the Nov 4 close of $12.31.
Does Intellia Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of NTLA is sold short?
44.4M shares, 38.6% of float, as of Oct 15, 2026.
What sector is NTLA in?
Healthcare, in the Diagnostics industry.

About Intellia Therapeutics

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

HQ: Cambridge, MA377 employeesListed May 6, 2016intelliatx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology